Middle East Pharmaceutical Industries Company (4016)의 가격은 얼마입니까?

Middle East Pharmaceutical Industries Company (4016)의 가격은 $17.36입니다.

Middle East Pharmaceutical Industries Company (4016)의 시가 총액은 무엇입니까?

Middle East Pharmaceutical Industries Company (4016)의 시가 총액은 $607.55M입니다.

Middle East Pharmaceutical Industries Company (4016) 수익

Middle East Pharmaceutical Industries Company (MEPIC), established in Riyadh, Saudi Arabia, in 1998, is a global pharmaceutical entity. The company's core activities encompass the entire lifecycle of generic medicines and various pharmaceutical products, from research and development to manufacturing and sales, catering to both local and international markets. Its business operations are strategically divided into private sector, public sector, and export divisions. MEPIC offers an extensive array of products designed to address a wide range of medical conditions. This includes dermatological treatments, remedies for respiratory ailments, central nervous system disorders, digestive issues, and musculoskeletal complaints, alongside medications for the urinary and reproductive systems. Furthermore, the company provides disinfectants and a diverse portfolio of therapeutic agents covering areas such as sexual health, diabetes, cardiovascular diseases, anti-infectives, anti-parasitics, pain relief, antiseptics, and general men's and women's health. These pharmaceutical and health products are supplied in numerous formats, including creams, ointments, syrups, capsules, tablets, gels, lotions, sprays, topical solutions, and personal hygiene items like hand sanitizers, mouthwashes, and soaps. In addition to its proprietary product lines, MEPIC leverages its manufacturing capabilities to offer contract manufacturing services. The company also specializes in cosmetic products, general health aids, and nutritional supplements. Originally known as Middle East Chemical Products Factory Company, the organization officially rebranded to Middle East Pharmaceutical Industries Company in January 2006.

연도	수익	변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.

연도

수익

변화

제공된 날짜에 대한 데이터가 충분하지 않습니다.

회사	수익	수익 차이	국가
Royalty Pharma plc RPRX.US	$1.35B	-	US
Swedish Orphan Biovitrum AB SOBI.ST	-	-	SE
Ipsen S.A. IPN.PA	-	-	FR
Recordati Industria Chimica e Farmaceutica S.p.A. REC.MI	-	-	IT
Sino Biopharmaceutical Limited 1177.HK	$992.42M	-	HK

회사

수익

수익 차이

국가